دورية أكاديمية
أعرض في EDS

Notes from the Field: Potential Outbreak of Extrapulmonary Mycobacterium abscessus subspecies massiliense Infections from Stem Cell Treatment Clinics in Mexico - Arizona and Colorado, 2022.

التفاصيل البيبلوغرافية
العنوان: Notes from the Field: Potential Outbreak of Extrapulmonary Mycobacterium abscessus subspecies massiliense Infections from Stem Cell Treatment Clinics in Mexico - Arizona and Colorado, 2022.
المؤلفون: Nguyen MH, Hasan NA, De Moura VCN, Epperson LE, Czaja CA, Johnston H, Laramee N, Orten K, Rivas J, Prasai S, Grossman MK, Perkins KM, Griffith DE, Khare R, Strong M, Daley CL
المصدر: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 May 09; Vol. 73 (18), pp. 420-422. Date of Electronic Publication: 2024 May 09.
نوع المنشور: Journal Article; Case Reports
اللغة: English
بيانات الدورية: Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE
أسماء مطبوعة: Publication: Atlanta, GA : U.S. Centers for Disease Control
Original Publication: [Atlanta] U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control.
مواضيع طبية MeSH: Disease Outbreaks* , Mycobacterium abscessus*/isolation & purification , Mycobacterium Infections, Nontuberculous*/epidemiology, Humans ; Colorado/epidemiology ; Adult ; Female ; Mexico/epidemiology ; Arizona/epidemiology ; Stem Cell Transplantation
مستخلص: Mycobacterium abscessus is an intrinsically drug-resistant, rapidly growing, nontuberculous mycobacterium; extrapulmonary infections have been reported in association with medical tourism (1). During November-December 2022, two Colorado hospitals (hospitals A and B) treated patient A, a Colorado woman aged 30-39 years, for M. abscessus meningitis. In October 2022, she had received intrathecal donor embryonic stem cell injections in Baja California, Mexico to treat multiple sclerosis and subsequently experienced headaches and fevers, consistent with meningitis. Her cerebrospinal fluid revealed neutrophilic pleocytosis and grew M. abscessus in culture at hospital A. Hospital A's physicians consulted hospital B's infectious diseases (ID) physicians to co-manage this patient (2).
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Reeti Khare reports uncompensated participation on a Clinical Laboratory Standards Institute Antimycobacterial Working Group and that her laboratory does contract work for Insmed, Inc., RedHill Biopharma, Paratek Pharmaceuticals, AN2 Therapeutics, Spero Therapeutics, and MannKind Corporation. David E. Griffith reports receipt of consulting fees from Insmed, Inc., AN2 Therapeutics, and Paratek Pharmaceuticals; payments or honoraria from Insmed, Inc.; and participation on data safety monitoring boards for NOMAB: Nebulised Nitric Oxide for Mycobacterium abscessus pulmonary disease and MannKind Corporation: Clofzimine inhalation suspension for pulmonary nontuberculous mycobacterial disease. Charles L. Daley reports institutional support from AN2 Therapeutics, Bugworks, Insmed, Inc., Juvabis, Paratek Pharmaceuticals, the Cystic Fibrosis Foundation, the Food and Drug Administration, the Patient-Centered Outcomes Research Institute, and the National Institutes of Health; receipt of consulting fees from Genentech and Pfizer; participation on data safety monitoring boards for Otsuka, the Bill and Melinda Gates Foundation, and Eli Lilly; and participation on advisory boards for AN2 Therapeutics, Astrazeneca, Hyfe, Insmed, Inc., MannKind Corporation, Matinas Biopharma, Nob Hill Therapeutics, Paratek Pharmaceuticals, Spero Therapeutics, and Zambon. Minh-Vu H. Nguyen reports receipt of an honorarium from the Oregon Health and Science University (OHSU) for a presentation at Nontuberculous Mycobacteria Research Consortium (NTMRC) 2023; support for travel to IDWeek 2023 and American Thoracic Society 2023 from National Jewish Health; and support for travel to NTMRC 2023 from OHSU. No other potential conflicts of interest were disclosed.
References: Emerg Infect Dis. 2016 Aug;22(8):1340-1347. (PMID: 27434822)
Ann Am Thorac Soc. 2021 Dec;18(12):1960-1969. (PMID: 33856965)
JAMA Netw Open. 2021 Oct 1;4(10):e2128615. (PMID: 34618037)
Emerg Infect Dis. 2023 Aug;29(8):1655-1658. (PMID: 37486227)
تواريخ الأحداث: Date Created: 20240509 Date Completed: 20240509 Latest Revision: 20240709
رمز التحديث: 20240710
مُعرف محوري في PubMed: PMC11095943
DOI: 10.15585/mmwr.mm7318a3
PMID: 38722805
قاعدة البيانات: MEDLINE
الوصف
تدمد:1545-861X
DOI:10.15585/mmwr.mm7318a3